2025 Q4 -tulosraportti
Vain PDF
97 päivää sitten
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·4 t sittenTook some profit at 8.00 That was smart..
·5 t sittenOnly days from 10 kr now, this will be great
·10 t sittenHIDDEN SAUCE: CIRCIO GAINS ACCESS TO THE INDUSTRY'S BEST TOOLS — WITHOUT BUILDING THEM THEMSELVES. 🧩🔑 Here's something almost no one thinks about. Everyone stares at circVec as if it's the entire value. It's not. It's half the story. Look at what the partners actually bring to the table: 👇 🔹 Acuitas — world-leading LNP technology (same class as behind the covid vaccines) 🔹 Tcelltech — nanoSMAR vector from Germany's cancer research center 🔹 GenAssist — tissue-specific AAV capsids 🔹 TraffikGene — peptide-based delivery 🔹 Avenue — AI-designed protein secretion Do you understand what's happening here? 🤯 Circio doesn't build all this themselves. They don't need to. They plug circVec into others' pre-developed, best-in-class technology. Each partner brings their own specialized expertise — and circVec makes it better. That means two things: 1️⃣ The value in Circio isn't just circVec. It's circVec PLUS access to an entire ecosystem of top-tier technology they gain through collaborations. 2️⃣ They save years and hundreds of millions they otherwise would have spent building delivery themselves. Others pay for the development. Circio combines. It's not one product. It's an engine that makes ALL the other tools in the industry better — and gains access to them into the bargain. 🏭 circVec is the core. But the surrounding ecosystem is an enormous, underestimated part of the value. We know what we own. ♟️🧱🍷
Good point. Important to clarify that what is currently underway is very extensive development and a number of studies based on circVec aimed at a number of major disease areas and many possible therapies. The agreement on July 16 with Avenue Biosciencies - further moved circVec towards a general RNA platform. The upside is also formidable for the partners as circVec could be precisely the technology needed for their own projects to succeed.- ·10 t sittenI think the share price will first gently move back towards the issue prices of 8.25 and 10.80 in the first days/week. Thereafter, it will rise further upwards before the presentation at the end of August; a price level of 15-20 might be possible. If good news comes at the half-year presentation, e.g., CAR-T poc, which should be possible now that it is quality assured, it could lead to a significant further boost. Mcap is now very low for a funded technology company with 5-600 mill in cash. A price in the range of 25 to 40 kr. during the autumn should be reasonably easily achievable with the potential that lies in, among other things, the Feasibility Study with Big Pharma and other technology collaborations. I expect that unexpected news may also come at the ESGCT annual meeting 2026 - 27 - 30 October this year, just like last year. Before that, they will attend 3 other conferences, including in China and 2 in the USA, during September / October. Market interest is expected to increase from larger funds and investors /foreign ones, where so far only DnB Global has made its entry. You don't have to agree with me on this, which is a personal assessment also based on international valuation of companies in the gene and cell therapy segment.
25-40 in price during the year is not an impossibility if good news comes forward. Some probably think it sounds like a lot, but I agree with GreatReset that it is absolutely possible.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
Vain PDF
97 päivää sitten
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·4 t sittenTook some profit at 8.00 That was smart..
- ·5 t sittenOnly days from 10 kr now, this will be great
- ·10 t sittenHIDDEN SAUCE: CIRCIO GAINS ACCESS TO THE INDUSTRY'S BEST TOOLS — WITHOUT BUILDING THEM THEMSELVES. 🧩🔑 Here's something almost no one thinks about. Everyone stares at circVec as if it's the entire value. It's not. It's half the story. Look at what the partners actually bring to the table: 👇 🔹 Acuitas — world-leading LNP technology (same class as behind the covid vaccines) 🔹 Tcelltech — nanoSMAR vector from Germany's cancer research center 🔹 GenAssist — tissue-specific AAV capsids 🔹 TraffikGene — peptide-based delivery 🔹 Avenue — AI-designed protein secretion Do you understand what's happening here? 🤯 Circio doesn't build all this themselves. They don't need to. They plug circVec into others' pre-developed, best-in-class technology. Each partner brings their own specialized expertise — and circVec makes it better. That means two things: 1️⃣ The value in Circio isn't just circVec. It's circVec PLUS access to an entire ecosystem of top-tier technology they gain through collaborations. 2️⃣ They save years and hundreds of millions they otherwise would have spent building delivery themselves. Others pay for the development. Circio combines. It's not one product. It's an engine that makes ALL the other tools in the industry better — and gains access to them into the bargain. 🏭 circVec is the core. But the surrounding ecosystem is an enormous, underestimated part of the value. We know what we own. ♟️🧱🍷Good point. Important to clarify that what is currently underway is very extensive development and a number of studies based on circVec aimed at a number of major disease areas and many possible therapies. The agreement on July 16 with Avenue Biosciencies - further moved circVec towards a general RNA platform. The upside is also formidable for the partners as circVec could be precisely the technology needed for their own projects to succeed.
- ·10 t sittenI think the share price will first gently move back towards the issue prices of 8.25 and 10.80 in the first days/week. Thereafter, it will rise further upwards before the presentation at the end of August; a price level of 15-20 might be possible. If good news comes at the half-year presentation, e.g., CAR-T poc, which should be possible now that it is quality assured, it could lead to a significant further boost. Mcap is now very low for a funded technology company with 5-600 mill in cash. A price in the range of 25 to 40 kr. during the autumn should be reasonably easily achievable with the potential that lies in, among other things, the Feasibility Study with Big Pharma and other technology collaborations. I expect that unexpected news may also come at the ESGCT annual meeting 2026 - 27 - 30 October this year, just like last year. Before that, they will attend 3 other conferences, including in China and 2 in the USA, during September / October. Market interest is expected to increase from larger funds and investors /foreign ones, where so far only DnB Global has made its entry. You don't have to agree with me on this, which is a personal assessment also based on international valuation of companies in the gene and cell therapy segment.25-40 in price during the year is not an impossibility if good news comes forward. Some probably think it sounds like a lot, but I agree with GreatReset that it is absolutely possible.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
2025 Q4 -tulosraportti
Vain PDF
97 päivää sitten
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·4 t sittenTook some profit at 8.00 That was smart..
- ·5 t sittenOnly days from 10 kr now, this will be great
- ·10 t sittenHIDDEN SAUCE: CIRCIO GAINS ACCESS TO THE INDUSTRY'S BEST TOOLS — WITHOUT BUILDING THEM THEMSELVES. 🧩🔑 Here's something almost no one thinks about. Everyone stares at circVec as if it's the entire value. It's not. It's half the story. Look at what the partners actually bring to the table: 👇 🔹 Acuitas — world-leading LNP technology (same class as behind the covid vaccines) 🔹 Tcelltech — nanoSMAR vector from Germany's cancer research center 🔹 GenAssist — tissue-specific AAV capsids 🔹 TraffikGene — peptide-based delivery 🔹 Avenue — AI-designed protein secretion Do you understand what's happening here? 🤯 Circio doesn't build all this themselves. They don't need to. They plug circVec into others' pre-developed, best-in-class technology. Each partner brings their own specialized expertise — and circVec makes it better. That means two things: 1️⃣ The value in Circio isn't just circVec. It's circVec PLUS access to an entire ecosystem of top-tier technology they gain through collaborations. 2️⃣ They save years and hundreds of millions they otherwise would have spent building delivery themselves. Others pay for the development. Circio combines. It's not one product. It's an engine that makes ALL the other tools in the industry better — and gains access to them into the bargain. 🏭 circVec is the core. But the surrounding ecosystem is an enormous, underestimated part of the value. We know what we own. ♟️🧱🍷Good point. Important to clarify that what is currently underway is very extensive development and a number of studies based on circVec aimed at a number of major disease areas and many possible therapies. The agreement on July 16 with Avenue Biosciencies - further moved circVec towards a general RNA platform. The upside is also formidable for the partners as circVec could be precisely the technology needed for their own projects to succeed.
- ·10 t sittenI think the share price will first gently move back towards the issue prices of 8.25 and 10.80 in the first days/week. Thereafter, it will rise further upwards before the presentation at the end of August; a price level of 15-20 might be possible. If good news comes at the half-year presentation, e.g., CAR-T poc, which should be possible now that it is quality assured, it could lead to a significant further boost. Mcap is now very low for a funded technology company with 5-600 mill in cash. A price in the range of 25 to 40 kr. during the autumn should be reasonably easily achievable with the potential that lies in, among other things, the Feasibility Study with Big Pharma and other technology collaborations. I expect that unexpected news may also come at the ESGCT annual meeting 2026 - 27 - 30 October this year, just like last year. Before that, they will attend 3 other conferences, including in China and 2 in the USA, during September / October. Market interest is expected to increase from larger funds and investors /foreign ones, where so far only DnB Global has made its entry. You don't have to agree with me on this, which is a personal assessment also based on international valuation of companies in the gene and cell therapy segment.25-40 in price during the year is not an impossibility if good news comes forward. Some probably think it sounds like a lot, but I agree with GreatReset that it is absolutely possible.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt